Role of human cytomegalovirus infection and the expression of immediate early gene products (CMV-IE) in the pathogenesis of vascular lesion formations
人巨细胞病毒感染和立即早期基因产物(CMV-IE)的表达在血管病变形成发病机制中的作用
基本信息
- 批准号:12470057
- 负责人:
- 金额:$ 9.22万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2000
- 资助国家:日本
- 起止时间:2000 至 2001
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We previously demonstrated that ;a) CMV-IE is expressed dominantly and specifically in the aortic walls in patients with inflammatory abdominal aortic aneurysms (IAAA). (Lab Invest 1996a, Nature Med 1998)b) CMV-IE gene transfer stimulates vascular smooth muscle cell proliferation in vitro and in vivo. (Biochem Biophys Res Common 1997)c) Vascular endothelial growth factor (VEGF) is abundantly expressed in the aortic wall of IAAA, and VEGF gene transfer to rabbit carotid arteries stimulated not only neointimal formation, but also "leaky, and angioma-like" fragile vessels in the neointima. (Lab Invest 1996b), however, there has been no study assessing the exact roles of CMV-IE in the inflammatory and angiogenic events in vessel wall.In the present study, we 1) tried to establish mouse lines expressing CMV-IE1 or CMV-IE2 specifically in vessel wall, and 2) assessed the molecular mechanisms of formation of "fragile" (alternatively, non-functional ) angiogenesis using recombinant viral vecto … More rs.1) Establishment of CMV-IE transgenic mice (TG) :To perform vessel specific expression of CMV-IE, we used murine preproendothelin-1 promoter. We obtained 2 lines of CMV-IE1 TG and 5 lines of CMV-IE2 in F1 generation, and gene expression assessments are now under evaluation. At this time, no apparent phenotype was found in each F1 animal. Establishment of F2 and generation of TG co-expressing CMV-IE1 and -IE2 are now assessed.2) Molecular mechanisms of formation of "fragile" angiogenesis :We tested effects of overexpression of VEGF165 using recombinant Sendai virus (SeV), as directly compared to FGF2 gene transfer. Intramuscular injection of SeV strongly boosted FGF2, resulting in significant therapeutic effects for limb salvage with increased blood perfusion associated with enhanced endogenous VEGF expression in murine models of critical limb ischemia. Incontrast, VEGF165-overexpression, 5-times higher than that of baseline on day 1, also strongly evoked endogenous VEGF in muscles, resulting in an accelerated limb amputation without recovery of blood perfusion. Interestingly, viable skeletal muscles of either VEGF165- or FGF2-treated ischemic limbs showed similar PCAM-1-positive vessel densities. Maturation of newly formed vessels suggested by smooth muscle cell actin-positive cell lining, however, was significantly disturbed in muscles with VEGF. Further, therapeutic effects of FGF2 were completely diminished by anti-VEGF neutralizing antibody in vivo, thus indicationg that endogenous VEGF does contribute to the effect of FGF2. These results suggest that VEGF is necessary, but should be delicately regulated to lower expression to treat ischemic limb. The therapeutic effect of FGF2, associated with the harmonized angiogenic effects seen with endogenous VEGF, provides important insights into therapeutic angiogenesis. Less
我们以前证明:a)CMV-IE主要特异性表达于炎性腹主动脉瘤(IAAA)患者的主动脉壁。(Lab Invest 1996 a,Nature Med 1998)B)CMV-IE基因转移在体外和体内刺激血管平滑肌细胞增殖。(Biochem Biophys Res Common 1997)c)血管内皮生长因子(VEGF)在IAAA的主动脉壁中大量表达,并且VEGF基因转移至兔颈动脉不仅刺激新生内膜形成,而且刺激新生内膜中的“渗漏和血管瘤样”脆弱血管。(Lab Invest 1996 b),然而,还没有研究评估CMV-IE在血管壁炎症和血管生成事件中的确切作用。在本研究中,我们1)试图建立在血管壁特异性表达CMV-IE 1或CMV-IE 2的小鼠品系,2)使用重组病毒载体评估“脆弱”(或者,无功能)血管生成形成的分子机制。 ...更多信息 rs.1)CMV-IE转基因小鼠(TG)的建立:为了进行CMV-IE的血管特异性表达,我们使用鼠前内皮素原-1启动子。我们在F1代获得了2个CMV-IE 1 TG系和5个CMV-IE 2系,目前正在评估基因表达评估。此时,在每只F1动物中未发现明显的表型。现在评估F2的建立和TG共表达CMV-IE 1和-IE 2的产生。2)“脆弱”血管生成形成的分子机制:我们测试了使用重组仙台病毒(SeV)过表达VEGF 165的效果,与FGF 2基因转移直接比较。肌内注射SeV强烈增强FGF 2,在严重肢体缺血的小鼠模型中产生显著的保肢治疗效果,其中增加的血液灌注与增强的内源性VEGF表达相关。与此相反,VEGF 165-过表达,5倍高于基线的第1天,也强烈诱发内源性VEGF在肌肉中,导致加速截肢没有恢复血液灌注。有趣的是,VEGF 165或FGF 2治疗的缺血肢体的存活骨骼肌显示出相似的PCAM-1阳性血管密度。平滑肌细胞肌动蛋白阳性细胞衬里提示新形成血管的成熟,然而,在VEGF的肌肉中明显受到干扰。此外,体内抗VEGF中和抗体完全减弱了FGF 2的治疗作用,因此表明内源性VEGF确实有助于FGF 2的作用。这些结果表明,VEGF是必要的,但应微妙地调节,以降低表达,以治疗缺血肢体。FGF 2的治疗作用与内源性VEGF的协调血管生成作用相关,为治疗性血管生成提供了重要的见解。少
项目成果
期刊论文数量(183)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hasegawa H, et al.: "Preclinical and therapeutic utility of HVJ-liposomes as a gene transfer vector for hepatocellular carcinoma using herpes simplex thymidine kinase"Cancer Gene Therapy. 8. 252-258 (2001)
Hasekawa H等人:“HVJ-脂质体作为使用单纯疱疹胸苷激酶的肝细胞癌基因转移载体的临床前和治疗效用”癌症基因治疗。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Takeushi K, et al.: "A simultaneous resection of a concomitant abdominal aortic aneurysm and hepatocellular carcinoma : two cases"Int Surg. 85. 152-157 (2000)
Takeushi K 等人:“同时切除并发腹主动脉瘤和肝细胞癌:两个病例”Int Surg。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Ishida M, et al.: "Immunohistochemical phenotypic alterations of rabbitt autologous vein grafts implanted under arterial circulation with or without poor distal runoff-implications of vein graft remodeling"Atherosclerosis. 154. 345-354 (2001)
Ishida M 等人:“动脉循环下植入的兔自体静脉移植物的免疫组织化学表型改变,有或没有静脉移植物重塑的远端径流不良影响”动脉粥样硬化。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kume M, et al.: "Administration of a decoy against the AR-1 binding site suppresses neointimal thickening in rabbit balloon injured arteries"Circulation. 105. 1226-1232 (2002)
Kume M 等人:“针对 AR-1 结合位点的诱饵的施用可抑制兔球囊损伤动脉中的新内膜增厚”循环。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Teramoto N, Yunoki T, Takano M, Yonemitsu Y, Masaki I, Sueishi K, Brading AF, Ito Y.: "Dual action of ZD6169, a novel K+ channel opener, on ATP-sensitive K+ channels in pig urethral myocytes"British Journal of Pharmacology. 133. 154-164 (2001)
Teramoto N、Yunoki T、Takano M、Yonemitsu Y、Masaki I、Sueishi K、Brading AF、Ito Y.:“ZD6169(一种新型 K 通道开放剂)对猪尿道肌细胞 ATP 敏感 K 通道的双重作用”英国杂志
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YONEMITSU Yoshikazu其他文献
YONEMITSU Yoshikazu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YONEMITSU Yoshikazu', 18)}}的其他基金
Development of"immunostimulatory virotherapy"to treat various malignancies
开发治疗多种恶性肿瘤的“免疫刺激病毒疗法”
- 批准号:
21390364 - 财政年份:2009
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Pathophysiological Mechanisms of Angiogenesis-Related Diseases
血管生成相关疾病的病理生理机制
- 批准号:
18390115 - 财政年份:2006
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic Research for Complex Molecular Mechanisms of the Process of the Functional Angiogenesis : toward the development of technologies controlling the molecular target of pathological angiogenesis.
功能性血管生成过程的复杂分子机制的基础研究:开发控制病理性血管生成分子靶标的技术。
- 批准号:
16390118 - 财政年份:2004
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Hierarchical Regulation of Multiple Angiogenic Growth Factors During 'Functional' Angiogenesis In Vivo
体内“功能性”血管生成过程中多种血管生成生长因子的分层调节
- 批准号:
14370072 - 财政年份:2002
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Deveelopment of Novel Gene Theray Strategies Using Recombinant Sendai Virus.
使用重组仙台病毒开发新的基因治疗策略。
- 批准号:
12557020 - 财政年份:2000
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似海外基金
Investigating the role of complement component 5a in ANCA-associated vasculitis
研究补体成分 5a 在 ANCA 相关血管炎中的作用
- 批准号:
MR/Y000854/1 - 财政年份:2024
- 资助金额:
$ 9.22万 - 项目类别:
Fellowship
Role of anti-transcobalamin receptor antibody in the pathogenesis of vasculitis
抗转钴胺受体抗体在血管炎发病机制中的作用
- 批准号:
23K19607 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Involvement of glycosylated IgA1 and its specific IgG in pediatric IgA nephropathy and IgA vasculitis with nephritis
糖基化 IgA1 及其特异性 IgG 在小儿 IgA 肾病和肾炎 IgA 血管炎中的作用
- 批准号:
23K07300 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MICA Investigating the role of cytomegalovirus reactivation in amplifying monocyte driven renal damage in active ANCA associated vasculitis
MICA 研究巨细胞病毒再激活在放大活动性 ANCA 相关血管炎中单核细胞驱动的肾损伤中的作用
- 批准号:
MR/X006964/1 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Fellowship
Neutrophil heterogeneity in anti-neutrophil cytoplasm antibody associated vasculitis
抗中性粒细胞胞质抗体相关性血管炎中的中性粒细胞异质性
- 批准号:
MR/X006131/1 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Fellowship
Glucocorticoids or Avacopan in peopLe with high-risk renal Anti-Neutrophil cytoplasm antibody associated vasculitis Trial (GALANT) - Pilot
糖皮质激素或 Avacopan 用于高危肾病患者抗中性粒细胞胞质抗体相关性血管炎试验 (GALANT) - 试点
- 批准号:
489796 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Operating Grants
Uncovering novel mechanisms and potential therapeutic targets for IgA vasculitis through GWAS and systems-level analysis of regulatory networks.
通过 GWAS 和调节网络的系统级分析揭示 IgA 血管炎的新机制和潜在治疗靶点。
- 批准号:
10723651 - 财政年份:2023
- 资助金额:
$ 9.22万 - 项目类别:
Novel therapeutic development of ANCA-associated vasculitis based on sphingosine-1-phosphate signaling.
基于 1-磷酸鞘氨醇信号传导的 ANCA 相关血管炎新疗法开发。
- 批准号:
22K08568 - 财政年份:2022
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of Japan collaborative registry of ANCA-associated vasculitis
建立日本 ANCA 相关血管炎协作登记处
- 批准号:
22K16348 - 财政年份:2022
- 资助金额:
$ 9.22万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluating the utility of adult-defined prognostic biomarkers in childhood onset primary chronic vasculitis
评估成人定义的预后生物标志物在儿童期发病的原发性慢性血管炎中的效用
- 批准号:
485919 - 财政年份:2022
- 资助金额:
$ 9.22万 - 项目类别:
Studentship Programs